Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1991-05-23
1993-08-10
Schenkman, Leonard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514530, A61K 3119, A61K 31557
Patent
active
052349535
ABSTRACT:
The present invention is concerned with the use of a compound of formula (I) ##STR1## wherein --W-- is ##STR2## wherein Z is --V(CH.sub.2).sub.b CO.sub.2 H where b is 1 or 2 and V is oxygen when b is 1 or methylene when b is 2;
REFERENCES:
patent: 4306075 (1981-12-01), Aristoff
patent: 4680288 (1987-07-01), Irmscher et al.
patent: 4971987 (1990-11-01), Vorbrueggen et al.
patent: 5013758 (1991-05-01), Skuballa et al.
patent: 5028628 (1991-07-01), Tadepalli et al.
patent: 5153222 (1992-10-01), Tadepalli et al.
Riegger A. J. G., Neurohumoral vasoconstrictor systems in heart failure, Eur. Heart J. 6: pp. 479-489, 1985.
Packer M., Neurohumoral interactions and adaptations in congestive heart failure, Circulation 77: pp. 721-730, 1986.
Dzau, V. J., Packer, M., Lilly, L. S., Swartz, S. L., Hollenberg, N. K., Williams G. H., Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia, N. England J. Med. 310: pp. 347-352, 1984.
Punzengruber, E., Stanek, B., Sinzinger H., Silbertbauer, F., Bicyclo-prostaglandin E.sub.2 metabolites in congestive heart failure and relation to vasoconstrictor neurohumoral principles, Am. J. Cardiol 57: pp. 619-623, 1986.
Yui, Y., Nakajama, H., Kawai, C., Murakami, T., Prostacyclin therapy in patients with congestive heart failure, Am. J. Cardiol. 50: pp. 320-324, 1982.
Auingor O., Virgolini, I., Weissel, M., Bergmann, H., Sinzinger, H., Prostacyclin I.sub.2 (PGI.sub.2) increases left ventricular ejection fraction (LVEF), Prosinglandine 36: pp. 149-254, 1989.
Yui, Y., Sakurai, T., Nakajina, H., Kawai, E., Effect of prostacyclin and prazocin in the treatment of congestive heart failure, with special reference in the sympathetic nervous system, Jpn. Circulation J., pp. 365-372, 1984.
Awan, N. A., Evenson, M. K., Needham, K. E., Beattie, J. M. Armsterdam, E. A., Mason T. T., Cardiocirculatory and myocardial energic effects of prostaglandin E.sub.1 in severe left ventricular failure due to chronic coronary disease, Am. Heart J., 102: pp. 703-709, 1981.
Popat, K. D., Pitt, B. P., Hemodynamic effects of prostaglandin E.sub.1 in patients with acute myocardial infarction and left ventricular failure. Am. Heart J. 103: pp. 485-489, 1982.
Jacobs, P., Naeije, R., Renard, M., Melot, C., Mois, P., Hallemmans, R., Effects of prostaglandin E.sub.1 on hemodynamic and blood gases in severe left heart failure, J. Cardiovascular Pharmacol. 5: pp. 170-172, 1983.
Yui, Y., Takatsur, Y., Hattori, R., Susawa, T., Sakaguchi, K., Yui, N., Kawai, C., Vasodilator therapy with a new stable prostacyclin analog, OP-41483, for congestive heart failure due to coronary artery disease and comparision of hemodynamic effects and platelet aggregation with nitroprusside, Am. J. Cardiol. 58: pp. 1042-1045, 1986.
Radernacher, P., Santak, B., Wust, H. J., Tarnow, J., Falke, J. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: Effects on pulonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 72: pp. 238-244, 1990.
Rubin, L. J., Mendoza, J., Hood, M., et al., Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprostenol), Results of a randomized trial. Annals Internal Medicine 112: 485-491, 1990.
Malik, K. U., Weis M. T., Jaiswal, N., Mechanism of action of adrenergic and cholinergic stimuli on cardiac prostaglandin, synthesis; pp. 327-330 In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 19 ed (B. Samulsson, PY.-K. Wong, F. F. Sun eds) Raven Press, Ltd., New York, 1989.
Omini, C., Daffonchio, L., Abbraccho, M. P., Cattabeni, F., Berti, F., Beta adrenoceptor desensitization in lung: A role for prostagiandins. pp. 524-527 In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 19 ed (B. Samuelsson, PY.-K. Wong, F. F. Sun eds), Raven Press, Ltd., New York, 1989.
Zusman R. M., Crow, J. W., Cato, A. E., Talkoff-Rubin N., Effects of prostacyclin infusion in uremic patients; Hematologic and hemodynamic response. Clin. Pharmaco. Ther 30: 251-257, 1981.
Olivari, M. T., Levine, T. B., Goldenbert, I. F., Cohn, J. N., Hemodynamic consequences of prostaglandin E.sub.2 activation of the renin-angiotensin system in heart failure, pp. 437-439 In: Advances in Prostacyclin, Thromboxane and Leukotriene, vol. 17 ed (B. Samuelsson, R., Paoletti, R. W., Ramwell eds) Raven Press, New York, 1987.
Dzau, V. J., Vascular and renal prostaglandin as counter-regulatory system in heart failure, European Heart Journal 9 (Suppl. H) pp. 15-19, 1988.
FitzFerald, G. A., Hossmann, V., Hummerich, W., Konrads, A., the renin-kallikrein-prostaglandin system; plasma active an inactive renin and urinary kallikrein during prostaglandin infusion in man, Prostaglandins and Medicine 5: pp. 445-456, 1980.
Fitzpatrick, T. M., Alter, I., Corey, E. J., Ramwell, E. J., Rose, J. C., Kot, P. A., Cardiovascular responses to PGI in the dog, Circ. Res. 42: pp. 192-194, 1978.
Dusting, G. J., Moncada, S., Vane, J. R., Prostaglandins, their intermediates and precursors; Cardiovascular actions and regulatory rates in normal and abnormal circulatory systems, Prigress in Cardiovascular Diseases 21: pp. 405-426, 1979.
Jentzer, J. H., Sonnerblick, E. H., Kirk, E. S., Coronary and systemic vasomotor effects of prostacyclin: implications for ischemic myocardium, pp. 323-338 In: Prostacyclin (J. R. Vane, S. Bergstrom eds) Raven Press, New York, 1979.
FitzGerald, G. A., Dargie, H. J., Watkins, J., Brown, M. J., Friedman, L. A., Lewis, P. J., Cardiac effects of prostacyclin in man, pp. 145-151 In: Clinical Pharmacology of Prostacyclin (P. J. Lewis, J. O'Grady eds) Raven Press, New York, 1981.
R. Berkow et al., "The Merck Manual of Diagnosis and Therapy", 15th edition, 1987, pp. 415-429, MSD Research Laboratories, Rahway, U.S., pp. 423-429.
Prostaglandins, Leukotrienes and essential fatty acids, vol. 43, No. 4, Aug. 1991, pp. 277-286, GB; R. P. Steffen et al.: "The effects of 15-AU81 a chemically stable prostacyclin renin-angiotensis systems of anesthetized dogs".
Walker A. Long and Lewis J. Rubin, Prostacyclin and PGE, Treatment of Pulmonary Hypertension; Am. Rev. Respir. Dis., 1987; 136; pp. 773-776.
American Heart Journal; Oct. 1984, vol. 108, No. 4, part 1; Siegel et al.
Hemodynamic effects of prostaglandin E.sub.1, et al., 1982, The C. V. Mosby Co., PGE.sub.1 hemodynamic effects in AMI with CHF; Popat and Pitt et al., pp. 485-489.
Effects of prostaglandin E.sub.1 on Hemodynamics and blood in severe heart failure, Journal of Cardiovascular Pharm. 5: pp. 170-171, 1983 Raven Press, New York.
PGE, Therapy of Severe CHF in CHAD; Awan et al., pp. 703-709, 1981.
Effects of Prostacyclin on the Contractile Performance of Cardiac Muscle (1); Arch. Int. Pharm., 256, pp. 161-162, 1982.
Effect of Prostacyclin on Vascular Capacity in the Dog, Fulghum et al., The American Society for Clin. Inv., Inc., vol. 76, pp. 999-1006; 1985.
Effective of Prostacyclin and Prazosin in the Treatment of Congestive Heart Failure; with Special Reference on the Sympathetic Nervous System, Yoshiki Yui et al., Jap. Circ. Journal, vol. 48, 1984.
Newman et al., Increased Myocardial Release of Prostacyclin in Dogs with Heart Failure, J. Cardiovascular Pharmacol. 5:194-201 (1983).
Stanek et al., Increase in Bicycloprostaglandin E2 Metabolite in Congestive Heart Failure in Response to Captopril, Clin. Cardiol., 12(2):97-101 (1989).
Elsner D., Kramer E. P., Riegger A. J. G. Hemodynamic, Hormonal and Renal Effects of the Prostacyclin Analogue Iloprost in Conscious Dogs with and without Heart Failure, J. Cardiovasc. Pharmacol., 16(4):601-608 (1990).
Long et al., Prostacyclin and PGE, Treatment of Pulmonary Hypertension 1,2 Am. Rev. Respir. Dis., 136:773-776 (1987).
Sprague et al., Differential Response of the Pulmonary Circulation to Prostaglandins E2 and F2a in the Presence of Unilateral Alveolar Hypoxia, J. Pharmacol. and Exp. Therap. 229:38-43 (1984).
Prostacyclin Therapy in Patients With Congestive Heart Failure, Yoshiki Yui, et al. The American Journ. of Cardiology; vol. 50; Aug. 1
Crow James W.
Long Walker A.
Brown Donald
Burroughs Wellcome Co.
Hrubiec Robert T.
Nielsen Lawrence A.
Schenkman Leonard
LandOfFree
Treatment of congestive heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of congestive heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of congestive heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1725549